...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer

Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer

Collaboration to evaluate ZEN-3694 in combination with Talazoparib in TNBC patients; Phase 1b/2 trial expected to initiate 1Q 2019

CALGARY, Alberta, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has entered into a clinical trial collaboration with Pfizer Inc. (“Pfizer”; NYSE: PFE) to evaluate the safety and efficacy of  a novel anti-cancer combination of Zenith’s investigational bromodomain and extra-terminal domain inhibitor (“BETi”), ZEN-3694, and Pfizer’s poly ADP ribose polymerase inhibitor (“PARPi”), talazoparib, in patients with locally advanced or metastatic triple negative breast cancer (“TNBC”).

“Zenith is excited to announce this partnership with Pfizer, a leader in oncology,” said Don McCaffrey, Chief Executive Officer of Zenith. “This novel approach of combining a BETi and a PARPi in patients who do not have inherited BRCA gene mutations may prove to significantly increase the potential of PARP inhibition in different indications, with an initial focus on triple negative breast cancer.”

Preclinical data indicate that combining talazoparib with ZEN-3694 is a rational combination to test in patients that are proficient in homologous DNA repair. BETi have been shown pre-clinically to modulate homologous DNA repair genes and can thus potentially sensitize  BRCA1/2 proficient patients to talazoparib.

Under the terms of the agreement, Zenith Epigenetics and Pfizer will collaborate on a Phase 1b/2 TNBC clinical study. Pfizer will provide talazoparib, Zenith will provide ZEN-3694, and both parties will fund the study. Zenith Epigenetics retains all rights to ZEN-3694.

About ZEN-3694

ZEN-3694 is a novel and selective investigational anti-cancer BETi. It is currently being developed in a Phase 2 metastatic castration resistant prostate cancer clinical study in combination with enzalutamide. Clinical data to date illustrate that ZEN-3694 is well tolerated at doses that modulate the target.

About Zenith:

Zenith Capital Corp. is a biotechnology investment company originally spun out of Resverlogix Corp. (TSX: RVX) in 2013. Zenith Epigenetics Ltd. (“Zenith”), a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need. Zenith is developing various novel combinations of BET inhibitors with other targeted agents.

For further information, please contact:

Investor Relations & Communications                            
Zenith Epigenetics
Phone: 587-390-7865
Email: [email protected]        
Website: www.zenithepigenetics.com

Share
New Message
Please login to post a reply